Dengue virus serotype 2-positive plasma was applied to two indirect single-molecule arrays (Simoas) for the detection of anti-dengue virus IgG and IgM. The Simoas were 1,000 and 10,000 times more sensitive than enzyme-linked immunosorbent assays (ELISAs) for the detection of IgG and IgM, respectively. Using Simoas, serology may be used for the detection of dengue virus infection in the acute phase.
T
he potential for early diagnosis of infectious disease in the acute phase of illness relies on the detection of ultralow concentrations of circulating pathogens and related biomarkers, such as host immunoglobulin, cytokines, DNA, and RNA. Subfemtomolar detection of proteins was recently demonstrated by capturing single molecules of disease-related biomarkers onto magnetic beads and then amplifying the signal by enzymatic amplification. The assay, coined single-molecule array (Simoa), has facilitated the ultrasensitive detection of prostate-specific antigen (PSA) (1), HIV p24 protein (2) , bacterial genomic DNA (3), tumor necrosis factor ␣ (TNF-␣), interleukin 6 (IL-6), IL-1␣, and IL-1␤ (4), and synthetic urinary biomarkers (5) using submilliliter clinical sample volumes (1) .
Dengue virus is a 50-nm arthropod-borne positive-sense RNA virus and is reemerging as one of the most globally important infectious diseases. The incidence of dengue virus infections has increased rapidly since the 1950s, currently affecting more than 100 countries worldwide (6) , with an estimated 3 billion persons at risk of infection (7) . When based solely on clinical observations, dengue is difficult to diagnose, as the disease state frequently mimics other febrile illnesses, such as influenza, measles, meningococcal infections, and enteric infections (8) . Current dengue diagnostic methods include virus isolation, nucleic acid and antigen detection, and serological tests; however, the performance of each method is predominantly dependent on assay sensitivity and the day of sample collection due to the complicated kinetics of viremia, NS1, and host antibody response. The reemergence of dengue and the complex clinical manifestations of infection make the need for rapid and accurate diagnostics of critical importance for clinical precision, control and prevention, and outbreak surveillance. In response to such a need, we developed two proof-ofconcept indirect Simoas for the ultrasensitive detection of type 2 anti-dengue virus IgG and IgM and compared the Simoa sensitivities to two commercially available EuroImmun dengue ELISA kits.
The indirect Simoa for the detection of either anti-dengue virus IgG or IgM follows precisely the same assay format as an indirect ELISA, utilizing inactivated dengue virus type 2 antigencoated magnetic beads for the capture of dengue virus-specific antibodies. Each captured antibody is detected by the addition of a biotinylated detector antibody specific to human IgG or IgM and labeled using streptavidin-␤-galactosidase (S␤G). Individual beads are then isolated in 46-fl reaction wells in the presence of a fluorogenic substrate, resorufin-␤-D-galactopyranoside (RGP), and sealed using a silicone gasket. Measuring the high local concentration of the fluorescent product in the reaction wells allows the detection of single antibody molecules. Enumeration of the number of active wells to inactive wells corresponds to the concentration of the IgG or IgM molecules in the original sample.
Due to the subjective nature of determining the onset of symptoms and the uncertainty behind primary versus secondary infections, we chose to measure assay sensitivity using serial dilutions of dengue virus serotype 2-positive plasma obtained from Fitzgerald Industries (catalogue no. 90-1002). For each assay, dengue virus serotype 2-positive plasma was diluted 1:100 to 1:10,000,000. For ELISAs, positive, negative, and borderline results were calculated as a ratio using a known calibrator (a standard containing dengue virus-specific IgG or IgM) specific to each ELISA kit and the fluorescence intensity (excitation coefficient) value of each sample. Samples were analyzed using a Tecan microtiter plate reader. A ratio of Ͼ1.1 indicates a positive signal, when the excitation coefficient generated by a sample (extinction coefficient of the patient sample/extinction coefficient of the calibrator) exceeds the value of the calibrator. For Simoas, imaging and analyses have been described previously (1, 4) . The fiber-optic microwell array used as the platform for the Simoa facilitates the singulation of beads and the ability to count "on" (enzymatically active) wells. Wells containing a bead and generating a 20% increase in fluorescent product over a 150-s imaging time (at 30-s intervals) are considered active. Images were acquired at the excitation and emission wavelengths for the resorufin product (9) using a charge-coupleddevice (CCD) camera and standard imaging optics (1). The fluorescence intensity generated by single-enzyme molecules (arrays with Ͼ10% active wells) was used to determine the average en-zyme per bead (AEB) based on the fluorescence intensity values of all other active beads (9) . The plasma was diluted in 25% fetal bovine serum. In the absence of dengue virus serotype 2-positive plasma, 25% fetal bovine serum served as the background (i.e., negative control) sample. The threshold for a positive signal was meanbackground ϩ 3 ϫ the standard deviation of the background.
According to the ELISA protocols, all samples should be diluted 1:100. The IgG ELISA detected plasma dilutions down to 1:10,000 with an observed IgG ratio of 4.13 at the recommended dilution of 1:100. The IgG Simoa detected anti-dengue virus IgG at the 1:10,000,000 dilution. These results demonstrate that the IgG Simoa was 1,000 times more sensitive than the EuroImmun IgG ELISA kit (Fig. 1) . The IgM ELISA detected the recommended 1:100 plasma dilution with an observed antibody ratio of 1.34. The IgM Simoa detected anti-dengue virus IgM at the 1:1,000,000 dilution. These results demonstrate that the IgM Simoa was 10,000 times more sensitive than the EuroImmun IgM ELISA kit (Fig. 2) . The IgG Simoa detected IgG at a dilution 1 order of magnitude greater than that of the IgM Simoa. These enhanced sensitivities suggest that the Simoas may be able to detect dengue virus infection at a much earlier stage of infection than the ELISAs.
Previous reports demonstrated the ultrasensitivity of singlemolecule arrays for detecting protein biomarkers (1, 4) . The data presented here demonstrate the enhanced sensitivities of Simoas for detecting antibodies and their potential use for the detection of dengue virus infection at a much earlier stage in the course of infection. Previous reports have emphasized the lack of sensitivity of serology in the first few days of illness, which has led to support for NS1 as a diagnostic marker due to our ability to measure it before antibodies can be detected (10) . In this study, we demonstrate the use of Simoas for the detection of antibodies in dengue virus infection. These data show measurable dengue virus-specific IgG and IgM that are missed with ELISAs. Until now, Simoas have been used only for the detection of protein biomarkers, genomic DNA, and synthetic urinary biomarkers. We detail the development of Simoas for two antibodies that demonstrate different kinetic profiles with respect to primary or secondary infections. Routinely, acute-and convalescent-phase serum samples for seroconversion are required for the serological diagnosis of infection. If a sample is collected prior to day 5 after the onset of symptoms, it is likely that defensive antibodies are circulating at undetectable levels (8, 10) . This study suggests that the effective use of serology with Simoa should be possible for the detection of dengue virus infection in the "transient window period" of illness previously diagnosable only with NS1, viral isolation, or RNA detection.
For future clinical validation, reverse transcriptase PCR-positive samples collected during the acute and convalescent phases of infection should be tested along with samples from other flaviviral infections to determine cross-reactivity. Using serology, this platform may provide a means to distinguish between primary and secondary infections and thus identify those at risk for developing dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS).
ACKNOWLEDGMENT
This study was funded in part by the Defense Advanced Research Projects Agency (contract HR0011-12-2-0001).
